Publications by authors named "I Sorokin N"

Lung cancer is the leading cause of mortality in both men and women due to genetic and epigenetic modifications. Our study focuses on fabricating phenmiazine ring leads by a functional group-based drug design to inhibit p53 -7A1W and MDM2-7AU9 proteins responsible for cancer cell growth. One hundred molecules are designed and allowed to bind inside the active site of 7A1W and 7AU9 protein using a glide dock platform and subjected to find MMGBSA.

View Article and Find Full Text PDF

Background:  Diabetic mononeuropathies, which are focal neuropathies, are less common than peripheral neuropathy in diabetes. They are frequently underreported or misdiagnosed due to mild or unnoticed cases. Early detection and treatment are crucial to prevent worsening nerve damage and complications.

View Article and Find Full Text PDF

Background: Telocytes are interstitial cells widely distributed in the extracellular matrix of numerous tissues distinguished by their long, thin, and moniliform projections. Telocytes have a role in the stimulation of angiogenesis and contribute to the development and progression of fibrosis.

Aim: The current study aimed to assess and compare the telocyte distribution in normal mucosa, oral submucous fibrosis (OSF), and OSCC associated with OSF (OSCCOSF).

View Article and Find Full Text PDF

Introduction Pseudoexfoliation (PXF) has a varied impact on the eye and has a complex relationship with pterygium and cataracts. We explored this study to estimate the proportion of PXF and its association with pterygium in cataract patients from a semi-arid district in South India. Methods This retrospective observational study was conducted at Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, a tertiary care referral center in Kolar, India.

View Article and Find Full Text PDF

Purpose: Overall survival (OS) is the gold standard end point for establishing clinical benefits in phase III oncology trials. However, these trials are associated with low success rates, largely driven by failure to meet the primary end point. Surrogate end points such as progression-free survival (PFS) are increasingly being used as indicators of biologic drug activity and to inform early go/no-go decisions in oncology drug development.

View Article and Find Full Text PDF